SightfileU.S. market data from official filings

GENMAB A/S (GMAB)

Name: GENMAB A/S (GMAB) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001434265 · EDGAR filings · Updated 2026-07-15

GENMAB A/S (GMAB) has 271 institutional managers reporting positions valued at $2.23B per the latest 13F reporting period.

Institutional managers

271

Reported 13F value

$2.23B

Latest updates

2026-07-15 — Foreign issuer report (6-K) filed
2026-06-29 — Foreign issuer report (6-K) filed
2026-06-17 — Foreign issuer report (6-K) filed
2026-06-16 — Foreign issuer report (6-K) filed
2026-06-15 — Foreign issuer report (6-K) filed
2026-06-15 — Foreign issuer report (6-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, GENMAB A/S has 271 institutional holders.

Related companies

CELLDEX THERAPEUTICS INC NEW (CLDX) · WARBY PARKER INC CL A COM (WRBY) · SUMMIT THERAPEUTICS INC (SMMT) · SAREPTA THERAPEUTICS INC (SRPT) · VIRIDIAN THERAPEUTICS INC (VRDN) · KODIAK SCIENCES (KOD)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-15.